Discontinuance of Bacille Calmette-Guérin Instillation Therapy for Nonmuscle-invasive Bladder Cancer Has Negative Effect on Tumor Recurrence

Urology

Volumn 73, Issue 6, 2009, Pages 1318-1322

  Takeda, Toshikazu ^a   Kikuchi, Eiji ^a   Yuge, Kazuyuki ^a   Matsumoto, Kazuhiro ^a   Miyajima, Akira ^a   Nakagawa, Ken ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER TUMOR; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FEVER; HEMATURIA; HUMAN; INDEPENDENT VARIABLE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PAPILLARY CARCINOMA; PREDICTOR VARIABLE; PRIORITY JOURNAL; TRANSURETHRAL RESECTION; TREATMENT WITHDRAWAL; TUMOR RECURRENCE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 67349228182     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.12.039     Document Type: Article

References (14)

1. Shelley M.D., Kynaston H., Court J., et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88 (2001) 209-216
2. Han R.F., and Pan J.G. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer?. A meta-analysis of randomized trials. Urology 67 (2006) 1216-1223
3. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
4. Orihuela E., Herr H.W., Pinsky C.M., et al. Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 60 (1987) 326-333
5. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. The side effects of bacillus Calmette-Guérin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a EORTC Genito-Urinary Group Phase III trial. Eur Urol 44 (2003) 423-428
6. Suzuki S., Shinohara N., Harabayashi T., et al. Complications of bacillus Calmette-Guérin therapy in superficial urothelial cancer: clinical analysis and implications. Int J Clin Oncol 7 (2002) 289-293
7. Sasaki K., Yokoyama M., Kanemura M., et al. Adverse effects of intravesical bacillus Calmette-Guérin instillation for superficial bladder cancer. J Annu Soc BCG BRM Immunother 20 (1998) 89-93
8. Irie A., Lee K.E., Kadowaki K., et al. Long-term results and complications of intravesical instillation of bacillus Calmette-Guérin for prophylaxis of bladder cancer recurrence. Hinyokika Kiyo 40 (1994) 873-877
9. Andius P., and Holmang S. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 93 (2004) 980-984
10. Luftenegger W., Ackermann D.K., Futterlieb A., et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guérin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 155 (1996) 483-487
11. Colombel M., Saint F., Chopin D., et al. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 176 (2006) 935-939
12. Al Khalifa M., Elfving P., Mansson W., et al. The effect of isoniazid on BCG-induced toxicity in patients with superficial bladder cancer. Eur Urol 37 suppl 1 (2000) 26-30
13. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E., et al. Has a 3-fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?. Results of a prospective randomized trial. J Urol 174 (2005) 1242-1247
14. Ojea A., Nogueira J.L., Solsona E., et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guérin (27 mg) versus very low-dose bacillus Calmette-Guérin (13.5 mg) versus mitomycin C. Eur Urol 52 (2007) 1398-1406